March 8, 2018 / 2:15 PM / 7 months ago

BRIEF-Bavarian Nordic Announces Phase 2 Trial Investigating Combination Of Its Immunotherapy CV301 And Nivolumab In Microsatellite Stable Colorectal Cancer

March 8 (Reuters) - Bavarian Nordic A/S:

* BAVARIAN NORDIC ANNOUNCES PHASE 2 TRIAL INVESTIGATING COMBINATION OF ITS IMMUNOTHERAPY CV301 AND NIVOLUMAB IN MICROSATELLITE STABLE COLORECTAL CANCER

* BAVARIAN NORDIC A/S - CO, ‍BRISTOL-MYERS SQUIBB AGREE TO SUPPLY CLINICAL MATERIAL FOR TRIAL​

* BAVARIAN NORDIC A/S - ‍PHASE 2 RANDOMIZED TRIAL WILL ENROLL UP TO 74 PATIENTS​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below